The value of clinical laboratory tests in the follow-up of breast cancer patients has been questioned due to their insensitivity and nonspecificity (Ormiston et al., 1985; Tomin & Donegan, 1987) . CEA has been the only tumour marker suitable in some cases for the monitoring of treatment in advanced breast cancer (Tormey & Waalkes, 1978; Mughal et al., 1983) . More sensitive and specific serum markers are required in the detection of tumour recurrence and in the monitoring of treatment response.
A radioimmunometric assay based on two different monoclonal antibodies (115 D8 and DF3) has been introduced for a breast cancer-associated antigen CA 15-3 (Kufe et al., 1984; Hilkens et al., 1984) . Preliminary clinical evidence indicates that in the follow-up of breast cancer CA 15-3 is more sensitive than CEA (Hayes et al., 1986; Wurz et al., 1986; Pons-Anicet et al., 1987) . In the present study we evaluated the sensitivity and specificity of CA 15-3 and the use of this assay in the follow-up of breast cancer patients.
Materials and methods
Serum samples were collected from 177 patients with primary breast cancer and from 58 age-adjusted patients with nonmalignant breast disease. All patients were operated in the Tampere University Central Hospital in [1981] [1982] [1983] [1984] [1985] . Both preoperative and postoperative (1-3 year follow-up) serum samples were obtained from 68 patients. The samples were stored at -70°C for 1-6 years before analysis. The patients were staged according to the TNM classification. In the postoperative period judgement of the presence or absence of tumour was based on clinical examination, chest and bone radiographs and in a few cases isotope scans.
Serum CA 15-3 levels were determined using an immunoradiometric assay kit (ELSA-CA 15-3, International CIS, Cedex, France). The reference range for serum CA 15-3 level was determined on the basis of values obtained from patients with non-malignant breast diseases (Mean +3 s.d.).
Results
The upper reference value for normal CA 15-3 value was set at 38 U ml -. In the preoperative period, markedly elevated serum CA 15-3 values were observed mainly in patients with Short-term follow-up (median 1.9 years) of the patients indicated 27% cumulative 3-year survival for cases with elevated preoperative serum CA 15-3 levels as compared to 84% for patients with normal serum levels (P<0.001, Mantel-Cox test) . Since this analysis was based on small numbers of patients with elevated values and short follow-up time it was not possible to determine whether CA 15-3 values had prognostic value independent of the TNM staging.
In serum samples obtained 1-5 years after operation CA 15-3 again showed a good correlation with clinical disease status ( Figure 2 ). About two-thirds of the patients with several metastases had elevated serum CA 15-3 values. One-third of the patients with a single (in most cases locoregional) metastasis and only 9% of patients with no clinical evidence of disease had increased serum values. One patient had markedly elevated serum CA 15-3 value without any clinical evidence of disease (Figure 2 ). At the time of blood sampling this patient apparently had subclinical disease because 13 months later an intra-abdominal breast cancer metastasis was diagnosed (Figure 3 (Sutherland & Mather, 1986; Harris & Hellman, 1986) after initial treatment, the chances of detecting such subclinical metastases are considerable. However, at the time being there is no evidence indicating that the earlier detection of metastatic disease by serial tumour marker assays is beneficial in terms of gained survival time.
Further research on subclinical metastatic breast disease and CA 15-3 levels is warranted before elevated serum levels could justify immediate therapeutic intervention.
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